Alladapt Immunotherapeutics has refilled the bank balance with $119 million in institutional financing from the likes of Novartis, which will be used to follow the biotech's dream of developing the first FDA-approved therapy to treat the majority of food allergy patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,